Alnylam Pharmaceuticals (ALNY) Stock Forecast, Price & News

Alnylam Pharmaceuticals (NASDAQ:ALNY) Frequently Asked Questions

Is Alnylam Pharmaceuticals a buy right now?

17 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last twelve months. There are currently 3 hold ratings and 14 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Alnylam Pharmaceuticals stock.
View analyst ratings for Alnylam Pharmaceuticals or view top-rated stocks.

When is Alnylam Pharmaceuticals' next earnings date?

Alnylam Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022.
View our earnings forecast for Alnylam Pharmaceuticals.

How were Alnylam Pharmaceuticals' earnings last quarter?

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) released its earnings results on Thursday, April, 28th. The biopharmaceutical company reported ($2.00) EPS for the quarter, missing analysts' consensus estimates of ($1.84) by $0.16. The biopharmaceutical company earned $186.90 million during the quarter, compared to the consensus estimate of $242.82 million. Alnylam Pharmaceuticals had a negative trailing twelve-month return on equity of 137.44% and a negative net margin of 101.46%. The firm's revenue for the quarter was up 37.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($1.71) earnings per share.
View Alnylam Pharmaceuticals' earnings history.

What guidance has Alnylam Pharmaceuticals issued on next quarter's earnings?

Alnylam Pharmaceuticals updated its FY 2022 earnings guidance on Monday, May, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $870.00 million-$930.00 million, compared to the consensus revenue estimate of $1.17 billion.

What price target have analysts set for ALNY?

17 brokers have issued twelve-month price objectives for Alnylam Pharmaceuticals' shares. Their forecasts range from $103.00 to $430.00. On average, they expect Alnylam Pharmaceuticals' stock price to reach $219.76 in the next twelve months. This suggests a possible upside of 66.1% from the stock's current price.
View analysts' price targets for Alnylam Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Alnylam Pharmaceuticals' key executives?

Alnylam Pharmaceuticals' management team includes the following people:

• Mr. Michael W. Bonney B.A., Exec. Chairman (Age 64, Pay $106.25k)
• Dr. Yvonne L. Greenstreet M.B.A., MBA, MBChB, CEO & Director (Age 59, Pay $1.24M)
• Dr. Akshay K. Vaishnaw M.D., Ph.D., Pres (Age 59, Pay $1.09M)
• Mr. Jeffrey V. Poulton M.B.A., CFO & Exec. VP (Age 54, Pay $893.47k)
• Dr. Alfred W. Boyle Ph.D., Chief Technical Operations & Quality Officer
• Dr. Kevin Joseph Fitzgerald Ph.D., Sr. VP, Head of Research & Chief Scientific Officer
• Ms. Christine Regan Lindenboom, Sr. VP of Investor Relations & Corp. Communications
• Ms. Indrani M. Lall Franchini J.D., Exec. VP, Chief Legal Officer & Sec. (Age 50)
• Mr. Mark Baglin, VP of Global Marketing
• Ms. Kelley Boucher, Chief Human Resource Officer

What is John M. Maraganore's approval rating as Alnylam Pharmaceuticals' CEO?

65 employees have rated Alnylam Pharmaceuticals CEO John M. Maraganore on Glassdoor.com. John M. Maraganore has an approval rating of 99% among Alnylam Pharmaceuticals' employees. This puts John M. Maraganore in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Alnylam Pharmaceuticals' key competitors?

Some companies that are related to Alnylam Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), United Therapeutics (UTHR), Repligen (RGEN), Neurocrine Biosciences (NBIX), Halozyme Therapeutics (HALO), Exelixis (EXEL) and Ionis Pharmaceuticals (IONS).
View all of ALNY's competitors.

What other stocks do shareholders of Alnylam Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alnylam Pharmaceuticals investors own include Alibaba Group (BABA), NVIDIA (NVDA), XOMA (XOMA), Ionis Pharmaceuticals (IONS), Gilead Sciences (GILD), NXP Semiconductors (NXPI), Mylan (MYL), AbbVie (ABBV), Micron Technology (MU) and Advanced Micro Devices (AMD).

What is Alnylam Pharmaceuticals' stock symbol?

Alnylam Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNY."

Who are Alnylam Pharmaceuticals' major shareholders?

Alnylam Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (8.96%), Baillie Gifford & Co. (8.39%), BlackRock Inc. (6.30%), Wellington Management Group LLP (5.82%), Capital World Investors (4.97%) and State Street Corp (2.41%). Company insiders that own Alnylam Pharmaceuticals stock include Akshay Vaishnaw, Barry E Greene, Jeffrey W Dunn, John Maraganore, Laurie Keating, Phillip A Sharp, Steven M Paul and Yvonne Greenstreet.
View institutional ownership trends for Alnylam Pharmaceuticals.

Which major investors are selling Alnylam Pharmaceuticals stock?

ALNY stock was sold by a variety of institutional investors in the last quarter, including Massachusetts Financial Services Co. MA, Baillie Gifford & Co., Polar Capital Holdings Plc, RTW Investments LP, Farallon Capital Management LLC, Loomis Sayles & Co. L P, Bellevue Group AG, and First Trust Advisors LP. Company insiders that have sold Alnylam Pharmaceuticals company stock in the last year include Akshay Vaishnaw, Jeffrey W Dunn, John Maraganore, Laurie Keating, Steven M Paul, and Yvonne Greenstreet.
View insider buying and selling activity for Alnylam Pharmaceuticals or view top insider-selling stocks.

Which major investors are buying Alnylam Pharmaceuticals stock?

ALNY stock was acquired by a variety of institutional investors in the last quarter, including Capital World Investors, Deep Track Capital LP, The Manufacturers Life Insurance Company , Eaton Vance Management, Wellington Management Group LLP, American Century Companies Inc., Vanguard Group Inc., and Twin Tree Management LP.
View insider buying and selling activity for Alnylam Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Alnylam Pharmaceuticals?

Shares of ALNY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Alnylam Pharmaceuticals' stock price today?

One share of ALNY stock can currently be purchased for approximately $132.27.

How much money does Alnylam Pharmaceuticals make?

Alnylam Pharmaceuticals has a market capitalization of $15.98 billion and generates $844.29 million in revenue each year. The biopharmaceutical company earns $-852.82 million in net income (profit) each year or ($7.490010) on an earnings per share basis.

How many employees does Alnylam Pharmaceuticals have?

Alnylam Pharmaceuticals employs 1,665 workers across the globe.

When was Alnylam Pharmaceuticals founded?

Alnylam Pharmaceuticals was founded in 2002.

What is Alnylam Pharmaceuticals' official website?

The official website for Alnylam Pharmaceuticals is www.alnylam.com.

How can I contact Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals' mailing address is 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at (617) 551-8200, via email at [email protected], or via fax at 617-551-8101.